Baseline patient characteristic and COVID-19 outcomes of the study population
| ICI population | |
| N=240 (%) | |
| Country | |
| UK | 47 (19.6) |
| Spain | 77 (32.1) |
| Italy | 90 (37.5) |
| Others | 26 (10.8) |
| Sex | |
| Female | 78 (32.5) |
| Male | 162 (67.5) |
| Age | |
| <65 years | 90 (37.5) |
| ≥65 years | 149 (62.1) |
| Missing | 1 (0.4) |
| Comorbidities | |
| No | 55 (22.9) |
| Yes | 185 (77.1) |
| Primary tumor | |
| Lung | 113 (47.1) |
| Melanoma | 51 (21.2) |
| Others | 76 (31.7) |
| Tumor stage | |
| Non-advanced | 37 (15.6) |
| Advanced | 190 (80.2) |
| Missing | 10 (4.2) |
| Tumor status at COVID-19 diagnosis | |
| Remission/in-response | 52 (21.7) |
| Active malignancy | 184 (76.7) |
| Missing | 4 (1.7) |
| SARS-CoV-2 vaccination status | |
| Unvaccinated | 182 (75.8) |
| Fully vaccinated | 42 (17.5) |
| Partially vaccinated | 3 (1.3) |
| Unkown | 13 (5.4) |
| COVID-19 outcomes | |
| N (rate, 95% CI) | |
| Oxygen therapy Missing | 81 (37.6, 29.9 to 46.8) 25 |
| COVID-19-specific therapy Missing | 114 (51.6, 42.5 to 61.9) 19 |
| Complications from COVID-19 | 73 (30.4, 23.8 to 38.2) |
| Hospitalization Missing | 131 (56.2, 47.0 to 66.7) 7 |
| ICU admission Missing | 22 (9.4, 5.9 to 14.3) 7 |
| 30-days case fatality rate Missing | 55 (23.6, 17.8 to 30.7) 7 |
COVID-19 outcomes' rates are provided in bold.
ICI, immune checkpoint inhibitor; ICU, intensive care unit.